Back to top
more

Bristol-Myers Squibb Company (BMY)

(Delayed Data from NYSE)

$58.59 USD

58.59
9,503,858

+0.08 (0.14%)

Updated Nov 15, 2019 04:00 PM ET

After-Market: $58.20 -0.39 (-0.67%) 7:03 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | B Growth | F Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Kinjel Shah

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

ABBV PFE AZN GSK MRK BMY LLY

Kinjel Shah

4 Big Drugmakers to Bet on After a Great Earnings Season

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

ABBV PFE NVO BMY MRK GSK JNJ

Zacks Equity Research

Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

MRK BMY LLY CLDX

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.

BMY AZN BAYRY AVEO

Zacks Equity Research

The Extreme Risks of Trading Your Own Retirement Assets - November 12, 2019

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

OMAB PSXP BMY

Zacks Equity Research

Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review

Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.

MRK BMY BAYRY RHHBY

Zacks Equity Research

Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

PFE MRK BMY AZN

Zacks Equity Research

4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY LLY ACAD CHRS CELG BIIB INCY ADPT ALEC NGM TAK

Zacks Equity Research

Want To Retire Early? Learn the Intelligent Investing Secret - November 11, 2019

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

CNP BMY CTRE

Zacks Equity Research

Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

BMY VRTX XLRN CELG

Zacks Equity Research

Novartis' Generics Unit to Buy Aspen's Japanese Operations

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

MRK BMY NVS GSK

Zacks Equity Research

Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

BMY IMMU CLVS ALKS

Kinjel Shah

Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

BMY SNY JNJ AGN AZN NVS NVO

Zacks Equity Research

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.

MRK LLY BMY NKTR

Zacks Equity Research

Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb

Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb

HPE GPI ABBV BMY EAT

Swayta Shah

5 Stocks With Solid Sales Growth to Keep an Eye on Right Now

Sustained sales growth is one of the most important characteristics of potential winners in the stock market. It provides investors an insight into product demand and pricing power.

BMY LDOS CSL ARCC SYK

Zacks Equity Research

The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb

The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb

HPE GPI BMY ABBV EAT

Sweta Jaiswal, FRM

Biotech ETFs in Focus on Impressive Q3 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

BMY FBT IBB XBI BBH AMGN BIIB CELG ALXN GILD

Sanghamitra Saha

Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

ABBV BMY MRK RHHBY LLY GSK XBI BBH AMGN BIIB CELG IDNA

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

PFE GSK MRK BMY

Zacks Equity Research

The Extreme Risks of Trading Your Own Retirement Assets - November 04, 2019

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

PSXP BMY LAMR

Zacks Equity Research

5 High-Flying Stocks Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

HPE GPI ABBV BMY EAT

Kinjel Shah

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

BMY MRK PFE GSK JNJ ABBV SNY

Zacks Equity Research

Company News for Nov 1, 2019

Companies in the news are: SBUX, KHC, TWTR, BMY

TWTR BMY KHC SBUX

Zacks Equity Research

Simple Secrets Anyone Can Use to Reach Early Retirement - November 01, 2019

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

BMY T SASR